Other languages NetraMark Holdings Inc.

Equities

AIAI

CA64119M1059

Market Closed - Canadian Securities Exchange Other stock markets 18:12:00 29/04/2024 BST			5-day change	1st Jan Change
0.305 ^CAD	-3.17%		-1.61%	-12.86%

04-10	Netramark's Ai-Based Clinical Solution Identifies Novel Lung and Colon Cancer Biomarkers and Patient Subpopulations	CI
04-04	NetraMark Holdings Inc. announces appointment of Jeff Huntsman to its strategic advisory board	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Netramark's Ai-Based Clinical Solution Identifies Novel Lung and Colon Cancer Biomarkers and Patient Subpopulations	04-10
NetraMark Holdings Inc. announces appointment of Jeff Huntsman to its strategic advisory board	04-04
NetraMark Holdings Inc. Signs Contract with Pharmaceutical Company to Deliver Clinical Trial Insights Regarding Efficacy and Placebo Response	03-12
NetraMark Presenting New Data Showing Ability of its Proprietary NetraAI Clinical Trial Solution in PD Insights	03-11
NetraMark Holdings Inc. Announces the Presentation of New Data Demonstrating the Ability of its Proprietary NetraAI Clinical Trial Solution	03-11
NetraMark Holdings Inc. Signs Fourth Contract with Large Biopharmaceutical Company to Enhance Clinical Trial	02-27
NetraMark Holdings Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-26
Netramark Holdings Inc. Announces Presentations of New Data Demonstrating the Application of Its Netraai Clinical Solution to Data Sets of Less Than 400 Patients	02-26
NetraMark Holdings Inc. to Present New Data Supporting the Potential of Its Proprietary NetraAI Clinical Trial Solution to De-Risk Clinical Trials	02-15
NetraMark Holdings Inc. Announces Launch of the NetraAI Lab Offering	02-12
NetraMark Up 8.6% After Reporting Third Contract With Biopharmaceutical Firm	01-30
Netramark Holdings Inc. Signs Third Contract with Biopharmaceutical Company	01-30
NetraMark Holdings Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	01-26
NetraMark's Generative AI Discovers Novel Rare Disease Drug Targets and Unique Patient Subpopulations That Could Substantially Improve Clinical Trial Success Rates	01-16
NetraMark Holdings Inc. Signs Two Contracts with Large Biopharmaceutical Company to Enhance Clinical Trial Insights	12-20
NetraMark Holdings Inc. Announces Management Changes	11-06
NetraMark Holdings Inc. Signs Master Service Agreement with Large Biopharmaceutical Company	31/10/23
NetraMark Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	17/08/23
NetraMark Holdings Inc. Appoints Dr. Maryanne Rizk to Its Strategic Advisory Board	19/07/23
NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	18/05/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages NetraMark Holdings Inc.

Equities

AIAI

CA64119M1059

Other languages

Filters